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ABSTRACT  
A series of new 20 corticosteroids were subjected to molecular property prediction. The Molecular, Physicochemical, and Biological properties 
were determined using Molinspiration Cheminformatics software. These compounds were further subjected to Toxicity Predictions using the 
Osiris Software. The calculated drug-related properties of the designed molecules were similar to those found in most marketed drugs. 
Amongst the proposed molecules, fourteen promising candidates can be considered as promising structures for the synthesis of new and more 
effective anti-asthmatic drugs. Result indicates that the derivatives are orally active molecules.  In-silico ADME and toxicity prediction was 
accomplished with the help of Swiss-ADMET tool provides the latest and most inclusive for diverse chemicals associated with known 
Absorption, Distribution, Metabolism, Excretion and Toxicity profiles. furthermore, BBB (Blood brain barrier) penetration, HIA (Human 
intestinal absorption), Caco-2 cell permeability and Ames test were calculated using ADMET web-based query tools incorporating a molecular 
build in interface enable the database to be queried by Smiles and structural similarity search. According to molecular docking results, 
derivatives No 4, 10 and 11 showed better docking Scores values compared to other derivatives and also dexamethasone and hydrocortisone.  
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INTRODUCTION 
Systemic oral corticosteroids (OCS) represent a class of 
drugs often used in the management of severe asthma. 
Despite their recognized safety risks, the updated report 
from the Global Asthma Initiative [1] recommends short-
term low-dose OCS for the management of exacerbations and 
as a supplement to maintenance therapy with corticosteroids 
inhaled (ICS) plus long-acting β2 agonists (LABA)) in severe 
asthma for better disease control [2]. However, only 
empirical evidence appears to support the effectiveness of 
OCS in reducing exacerbation. In addition, a recent 20-year 
observational study in severe asthma patients showed that 
those who were addicted to OCS had high mortality (50% of 
patients died) and had high exacerbation rates [3]. Emerging 
biological agents targeting molecular pathways of asthma 
have shown great promise in reducing the need for OCS [4]. 
Omalizumab, targeting immunoglobulins E (IgE), reduces 
exacerbations in patients with severe allergic asthma, 
regardless of the number of blood eosinophils [5]. Other 
biologics targeting specific interleukins (IL), such as anti-IL5 
(mepolizumab and reslizumab), anti-IL5 R α (benralizumab) 
and anti IL4 Rα (dupilumab) also reduce exacerbations in 
patients with severe eosinophilic asthma, without the main 
safety concerns that overshadow the OCS. As a first-line 
treatment in severe asthma, GINA recommends adding these 
biological agents and / or long-acting muscarinic antagonists 
(LAMA) to an ICS and LABA combination [1], Inhaled 
corticosteroids (ISC ) are still the first-line anti-inflammatory 
therapy for persistent asthma of all severities [6]. In fact, 
they reduce the inflammation of the respiratory tract and, 
therefore, influence hyperresponsiveness. In this way, CSIs 
improve lung function and the severity of symptoms [7]. 
They are also effective in preventing or reducing the rate of 
asthma exacerbations. The anti-inflammatory activity of ICS 
is linked to their ability to target all the cells involved in 
asthmatic inflammation [8]. There is strong evidence that ICS 
suppress the expression and release of a large amount of 
inflammatory mediators and growth factors for epithelial 
cells in the primary respiratory tract, possibly via targeting 
nuclear factor or activator protein 1 (AP- 1) and by 
modulating the acetylation / deacetylation of histones [9] 
Corticosteroid receptors, including GR and MR, are widely 
expressed in the body and are implicated in many diseases 
and health outcomes. GR and MR mediate the actions of 
glucocorticoids and mineralocorticoids, respectively 
belonging to a family of steroids involved in many 
physiological processes. Disturbances in the action of 
glucocorticoids have been linked to birth defects, mood and 
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cognitive disorders, cancer, immune diseases, allergic 
diseases, metabolic dysfunctions, and cardiovascular 
diseases [10]. 
Several ICSs have been approved for the treatment of 
asthma. They include beclomethasone dipropionate, 
budesonide, ciclesonide, flunisolide, fluticasone furoate, 
fluticasone propionate, mometasone furoate and 
triamcinolone acetate. The profile of each ICS is critically 
influenced by the difference in their characteristics [11], but 
also, it is important to note that the significant differences in 
the selectivity, potency and physicochemical properties of 
glucocorticoid receptors (GR) are essential for defining the 
PD profile of an ICS [12]. 
The aim of this study is to create a novel inhibitor in the 
treatment of asthma disease based on the understanding of 
the structure-activity relationship carried out in a previous 
study [13]. To release this work, Molinspiration 
Cheminformatics, Osiris Software, Swiss-ADMET and 
(Schrodinger, Maestro) software were used. 
COMPUTATIONAL STUDIES 
For predicting the pharmacokinetic and drug-likeness 
properties of the major compounds of Hydrocortisone 
derivatives, the following online platforms were used: 
SwissADME, Molinspiration and Osiris Data Warrior. 
SwissADME enables predictions for passive human 
gastrointestinal absorption (HIA) and blood-brain barrier 
(BBB) permeation of compounds, as well as the assessment 
of whether a compound is a substrate of P-gp and an 
inhibitor of CYP isoenzyme family. The knowledge about 
compounds being substrates or non-substrates of P-gp is 
essential for the evaluation of active efflux through biological 
membranes. The risks of toxicity (mutagenicity, 
tumorigenicity, irritability and reproductive effects) and the 
physicochemical properties (drug similarity and drug score) 
for compounds 1-20 were calculated by the methodology 
developed by Osiris. Various types of toxicities including 
oncogenicity, neurotoxicity, teratogenicity, immunotoxicity, 
etc. were generated and toxicity profile of molecule noted. 
Molinspiration Cheminformatics offers broad range of tools 
supporting molecule manipulation and processing, including 
SMILES and SDfile conversion by giving information about 
physicochemical descriptors and bioactivity relevant 
properties. All the parameters for drug-likeness were 
predicted and calculated according to the Lipinski’s rule-of-
five. Moreover, to better understand the affinity between the 
drug and the receptor, molecular docking was carried out 
using Maestro version 11.1 Software. 
 
    
 
 
  
 
   
    
   
 
  
Figure 1: Molecular structure of the compounds (1-20) and standard drugs. 
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RESULTS AND DISCUSSION 
Toxicity prediction 
The toxicity risk predictor locates fragments that indicate a 
potential risk of toxicity in a molecule [14]. Toxicity risk 
alerts indicate that the drawn structure may be dangerous 
for the specified risk category. From the data presented in 
the Table 1. , it is obvious that the analyzed compounds are 
supposed to be non-mutagenic, non-tumorigenic, non-
irritant and without effects on reproduction with the 
exception of molecule 2, 3, 8, 12, 15 and 18 which is at low 
risk compared to  the natural hormone. 
The aqueous solubility of a compound significantly affects its 
absorption and distribution characteristics. Typically, low 
solubility is accompanied by poor absorption and, therefore, 
the general objective is to avoid poorly soluble compounds. 
Our estimated (log S) value is a basic (stripped) logarithm of 
the solubility of a compound. It should be noted that more 
than 80% of the drugs on the market have an (estimated) log 
value greater than -4. In the case of compounds 1-20, 9 
elements have an acceptable aqueous solubility while a 
single compound is very soluble. 
 Drug resemblance is defined as a complex balance between 
various molecular properties and structural characteristics 
showing whether a molecule is like known drugs [15]. it 
should be mentioned that a positive value indicates that the 
designed molecule contains fragments which are frequently 
present in commercial drugs. 
The data obtained Table 1. revealed that the analyzed 
compounds have positive drug similarity values and 
therefore there is a presence of the fragments in the 
commercial drugs. In contrast, 13 items in the set have 
higher drug similarity values than the standard drug, 
namely: dexamethasone. 
The drug score combines drug similarity, miLogP, solubility, 
molecular weight and toxicity risks into a practical value 
that can be used to judge the overall potential of the 
compound to qualify for a drug [16]. indeed, a value of 0.5 or 
more makes the compound a promising advance for the 
development of future safe and effective drugs. in addition, 
three compounds have been found to be less than the typical 
value, but this does not indicate that these drugs are not 
effective compared to the natural hormone 
(hydrocortisone). The overall drug score values for most of 
the compounds have good drug score values. 
 
Table 1: Toxicity risks, drug-likeness, and drug score of compounds (1-20) and standard drugs 
Comp. N° 
Toxicity Risks 
Solubility 
Drug-
likeness 
Drug 
score Mutagenicity Tumorigenicity Irritancy 
Reproductive 
effects 
1     -4.80 2.13 0.53 
2     -3.91 3.11 0.59 
3     -4.62 3.54 0.59 
4     -4.25 2.86 0.68 
5     -4.98 5.35 0.54 
6     -3.75 1.91 0.73 
7     -4.29 3.05 0.69 
8     -1.92 5.22 0.82 
9     -4.95 5.01 0.53 
10     -4.24 4.23 0.66 
11     -3.56 4.35 0.79 
12     -3.48 5.62 0.78 
13     -4.67 5.82 0.58 
14     -3.78 6.14 0.74 
15     -5.27 3.02 0.47 
16     -2.05 3.88 0.79 
17     -3.77 5.10 0.74 
18     -5.39 1.42 0.43 
19     -5.28 6.94 0.49 
20     -3.12 6.25 0.78 
Dexamethasone     -3.25 3.17 0.79 
Hydrocortisone     -3.18 3.31 0.49 
                              : Not toxic;                           :  Slightly toxic ;                        : Highly toxic. 
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Molecular properties and drug-likeness 
In the framework of our study, the conformity of the 
compounds to the Lipinski rule of five was evaluated [14] 
this simple rule is based on the observation that most 
biologically active drugs have a molecular weight of 
approximately 500 or less, logP values not exceeding 5, 
hydrogen donor sites of not more than 5, and hydrogen bond 
acceptor sites not greater than 10. In addition, the polar 
topological surface (TPSA) and the number of rotary links 
have been linked to the bioavailability of drugs [15]. 
Molecular properties (TPSA, nrotb, miLogP, OH-NH 
interaction, ON interaction, molecular weight and number of 
violations of Lipinski's rule) of the compounds were 
calculated using molinspiration software and compared to 
the values of standard drugs: dexamethasone and the natural 
hormone (Hydrocortisone). Drug distribution results from 
tissue diffusion which itself depends on drug size and 
lipophilicity, therefore prediction of permeability across 
gastrointestinal epithelial cells, the blood-brain barrier and 
the brain, which can help interpret pharmacokinetic results 
and understand the behavior of these products in the body 
[17]. On the other hand, highly lipophilic drugs will only be 
absorbed after dissolving in the digestive tract. This is 
confirmed by lipinski, the value of miLogP must be estimated 
between 0.4 and +5 [18]. The polar topological surface 
(TPSA) is a very useful parameter for predicting the drug 
transport properties. It gives information on the polarity of 
molecules. TPSA is calculated on the basis of the 
methodology published by Ertl et al. [19]. It is defined as the 
sum of the surfaces of the polar atoms usually, oxygen, 
nitrogen, sulfur, chlorine, and hydrogen in a molecule. Thus, 
it is closely linked to the hydrogen bonding potential of a 
compound. TPSA has been shown to be a very good 
descriptor characterizing drug absorption, including 
intestinal absorption, bioavailability, and penetration of the 
blood-brain barrier. Molecules with TPSA values of around 
140 Å2 or more should exhibit poor intestinal absorption 
[20]. Considering these recommendations, the results 
presented in the table indicate that all the compounds 
analyzed have TPSA values. <140 Å2. So, they should have 
good intestinal absorption. 
The number of rotatable bonds is used to identify the 
flexibility of the molecule. it has been shown that to be a drug 
with very good oral bioavailability, and for a chemical 
structure to be similar to drugs, according to Lipinski's rule, 
the number of rotatable bonds must be less than or equal to 
5. Among all the compounds tested, 2.6 and 7 were rigid 
because they have no rotary bond. All the compounds tested 
have rotatable bonds <5 and they may not have problems of 
bioavailability according to the results cited in (Table 2.). 
Furthermore, all the compounds fulfill the Lipinski rule [21], 
which implies a good oral bioavailability. 
 
Table 2: Physicochemical property of the compounds (1-20) and standard drugs. 
Compd. N° 
Molecular properties 
Volume TPSA a n-ROTB b HBA c HBD d miLogP e MW f 
Lipinski’s 
violations 
Rule _ _ _ < 10 < 5 ≤ 5 < 500 ≤ 1 
1 426.12 87.74 4 5 2 4.11 492.74 0 
2 345.13 63.60 0 4 1 2.50 392.44 0 
3 416.97 96.97 4 6 2 3.57 476.52 0 
4 361.48 74.60 3 4 2 3.06 430.49 0 
5 429.53 86.62 4 5 3 3.29 491.60 0 
6 328.55 63.60 0 4 1 2.02 378.42 0 
7 361.72 63.60 0 4 1 2.86 406.47 0 
8 393.68 99.76 3 6 3 1.92 425.52 0 
9 426.12 83.83 4 5 2 4.21 492.58 0 
10 388.68 74.60 3 4 2 3.39 456.53 0 
11 349.50 100.62 1 5 4 1.58 395.45 0 
12 367.17 86.92 1 5 3 1.96 409.47 0 
13 461.75 95.86 5 6 3 3.18 499.67 0 
14 383.97 86.62 2 5 3 2.33 423.50 0 
15 442.25 74.60 4 4 2 4.97 486.70 0 
16 398.29 99.76 3 6 3 1.91 443.51 0 
17 376.16 95.86 2 6 3 1.92 425.47 0 
18 441.35 87.74 4 5 2 3.58 488.57 0 
19 453.12 86.62 4 5 3 3.99 483.67 0 
20 384.11 77.84 1 5 2 1.76 423.50 0 
Dexamethasone 358.07 94.83 2 5 3 2.06 392.47 0 
Hydrocortisone 343.36 94.83 2 5 3 1.62 362.47 0 
a Topological polar surface area;  
b number of rotatable bonds;  
c number of hydrogen bond acceptors; 
d number of hydrogen bond donors;  
e logarithm of partition coefficient between n-octanol and water; 
f MW. molecular weight. 
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Bioactivity score 
The bioactivity scores of the compounds for the drug targets 
have also been predicted by Molinspirations and are 
presented in the Table 3. A molecule with a bioactivity 
scores greater than 0.00 is likely to exhibit considerable 
biological activity, while values between - 0.50 and 0.00 are 
moderately active and if the score is less than - 0.50, it is 
presumed to be inactive [22]. 
Corticosteroids have the originality of exerting their actions 
through essentially genomic effects where all the 
compounds presented in the Table 3. indicate positive 
values. These results suggest that the new compounds have 
shown promising properties, in terms of binding to the 
nuclear receptor in order to exercise transcriptional activity 
there. In addition, the data were compared to standard 
references, indicating that 11 compounds have a better 
bioactivity score on the nuclear receptor than the reference 
standard, more precisely dexamethasone (see Table 3.) This 
makes the hypothesis that these elements may be more 
effective therapeutically possible. 
GCs also induce rapid effects occurring within minutes or 
even seconds of their application. In fact, inhibiting the 
activation of protein G abolishes the rapid effects of 
glucocorticoids. The results presented in the table. Indicate 
that the compounds 5,13,15 and 19 have values between -
0.18 to 0.04 of GPCR ligand; so, they should have a moderate 
genomic effect. On the other hand, the non-genomic actions 
of the other compounds presented in the Table 3. have a 
better score than the reference therefore these structures 
could also be important from a clinical point of view, 
because the GC induce short-term therapeutic effects in 
patients with asthma, rheumatoid arthritis, and allergic 
rhinitis [23]. 
Protein kinases appear to be essential protagonists in the 
regulation of cell signaling pathways. Indeed, these enzymes 
play a fundamental role in cell growth and differentiation as 
well as in apoptosis phenomena. The inhibition of the latter 
causes many undesirable effects. Unfortunately, 6 
compounds analyzed can cause these effects moderately 
(Table 3.). 
The results clearly reveal that the compounds analyzed, and 
dexamethasone could inhibit proteases and other enzymes.
 
Table 3: Bioactivity score of the compounds according to Molinspirations Cheminformatics. 
Compd. N° 
Drug-likeness 
GPCRL ICM KI NRL PI EI 
1 0.07 -0.26 -0.78 1.30 0.67 0.62 
2 0.18 0.07 -0.54 1.73 0.94 0.78 
3 0.04 -0.15 -0.59 1.35 0.59 0.59 
4 0.22 0.06 -0.55 2.06 1.03 0.95 
5 0.00 -0.20 -0.50 1.19 0.62 0.54 
6 0.24 0.11 -0.42 1.79 0.93 0.83 
7 0.16 -0.01 -0.54 1.66 0.94 0.74 
8 0.16 -0.22 -0.42 1.01 0.20 0.66 
9 0.07 -0.08 -0.52 1.45 0.68 0.64 
10 0.14 -0.01 -0.71 1.80 0.94 0.86 
11 0.23 0.03 -0.43 1.78 1.03 0.82 
12 0.27 -0.03 -0.50 1.70 1.06 0.80 
13 -0.15 -0.37 -0.58 0.56 0.01 0.33 
14 0.25 -0.06 -0.52 1.62 0.98 0.76 
15 -0.11 -0.39 -0.82 0.81 0.14 0.46 
16 0.17 -0.18 -0.45 1.32 0.60 0.76 
17 0.23 -0.09 -0.36 1.60 1.13 0.88 
18 0.13 -0.15 -0.63 1.39 0.66 0.61 
19 -0.18 -0.45 -0.66 0.62 -0.03 0.34 
20 0.23 -0.01 -0.43 1.67 0.94 0.72 
Dexamethasone 0.03 -0.21 -0.81 1.59 0.76 0.78 
Hydrocortisone -0.00 -0.29 -0.85 1.17 0.09 0.63 
GPCRL: GPCR ligand, ICM: ion channel modulator, KI: kinase inhibitor, NRL: nuclear receptor ligand, PI: protease inhibitor, EI: 
enzyme inhibitor. 
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ADMET prediction for the proposed compounds 
One of the essential qualities of a drug is its ability to cross 
the intestinal membrane (absorption) to then reach the 
systemic circulation: this is called the bioavailability of a 
drug. Among the many transporters present in the intestinal 
membrane, we find the P-gp which is part of the ABC 
transporters. It is present in the apical membrane of 
epithelial cells of the gastrointestinal tract. It plays a 
protective role by preventing the passage of potentially 
dangerous molecules from the intestine into the blood. Many 
drugs are found to be substrates for this transporter 
(Colchicine, azithromycin, losartan, lopinavir, 
dexamethasone, etc.), which limits their bioavailability and 
reduces the treatment efficiency [24]. The results presented 
in the table indicate that all the compounds are substrates of 
P-gp, but they remain very permeable to the intestinal 
membrane with the exception of compound 15. On the other 
hand, Drug metabolism is a crucial step in the detoxification 
and elimination of drugs by chemical conversion to more 
hydrophilic molecules whose elimination by body fluids is 
facilitated. Only a few CYPs are strongly involved in the 
transformation and elimination of active ingredients in 
humans. These are CYP 1A2, 2A6, 2B6, 2C9 / 19, 2D6, 2E1 
and 3A4. Inhibition of CYP and other enzymes in drug 
metabolism can affect the clearance and consequently the 
serum level of these drugs. The therapeutic effectiveness of a 
drug or its active form can also be varied. Therefore, the 
concomitant oral administration of a CYP3A4 inhibitor and a 
drug that is a substrate for the same isoenzyme can lead to a 
very large increase in the plasma concentration of the drug 
and thus lead to increased toxicity. ABC 
Exploring these parameters may offer new strategies that 
could bridge the gap between early stage drug discovery, 
preclinical and clinical trials, as well as gain insight into their 
reaction in the body, allowing the chemist Medicinal to 
introduce new functional groups on the molecule to dodge 
the metabolic pathways capable of giving very polar 
compounds which can be eliminated very easily from the 
body. As a result, it can help synthesize metabolically stable 
drugs, as well as avoid drug interactions. For this purpose, 
the compounds were submitted to learn the potential of 
compounds having inhibitor of CYP with human hepatic 
microsomes CYP (Table 4.). Only the compounds 6,7,8,11 
and 16 are not inhibitors of all CYP. 
 
Table 4: Pharmacokinetics of compounds. 
Compd. N° 
GI 
absorptiona 
BBB 
permeantb 
P-gp 
substratec 
CYP1A2 
inhibitor 
CYP2C19 
inhibitor 
CYP2C9 
inhibitor 
CYP2D6 
inhibitor 
CYP3A4 
inhibitor 
1 High No Yes No No No No Yes 
2 High Yes Yes No No No No No 
3 High No Yes No No No No Yes 
4 High No Yes No No No No Yes 
5 High No Yes No No No No Yes 
6 High Yes Yes No No No No No 
7 High Yes Yes No No No No No 
8 High No Yes No No No No No 
9 High No Yes No No No No Yes 
10 High No Yes No No No No Yes 
11 High No Yes No No No No No 
12 High No Yes No No No No Yes 
13 High No Yes No No No No Yes 
14 High No Yes No No No No Yes 
15 Low No Yes No No Yes No No 
16 High No Yes No No No No No 
17 High No Yes No No No No Yes 
18 High No Yes No No No No Yes 
19 High No Yes No No Yes No Yes 
20 High Yes Yes No No No No Yes 
Dexamethasone High No Yes No No No No No 
Hydrocortisone High No Yes No No No No No 
a: Gastrointestinal absorption; b: Blood brain barrier; c: Permeability-Glycoprotein; CYP: Cytochrome P450; Log Kp: skin 
permeation. 
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Molecular docking analysis  
Molecular docking is used to predict the binding mode of 
ligands within the binding site of target proteins [25]. 
Protein enhancement and grid generation are required steps 
for suitable docking.  A protein, PDB ID: 1M2Z was retrieved 
in PDB format from Protein data bank from which the three-
dimensional X-ray crystallographic structure of human 
glucocorticoid receptor (PDB ID: 1M2Z) was taken. Protein 
preparation Wizard of Maestro version 11.1 was used for 
refining the structure while the removal of water and 
optimization of H-bond was done. Minimization of heavy 
atom molecule at RMSD (0.30Å) by using force filed 
OPLS2005 were used to release the process of minimization. 
Protein was prepared by eliminating water molecules, 
needless atoms, removing the alternate conformations and 
adding hydrogen. 
The grid generation describes a region in a receptor where 
binding interaction can happen. Before launching the 
molecular docking, the geometry of all molecules needs to be 
optimized (Vora et al., 2019). There are basically four steps 
involved in the docking scores which include HTVS (high-
throughput virtual screening), SP (standard precision), XP 
(extra precision) docking, and followed by MM-GBSA based 
binding free energy calculation for top-scored ligand-protein 
complexes. 
The docking scores results of the investigated molecules are 
illustrated in Table 5.; the scores are arranged in descending 
order from smallest the negative value to the majority 
negative value. It was found that all molecules have poses in 
the receptor site, and two molecules with better scores when 
compared to the score of the marketed molecule 
(Hydrocortisone). Furthermore, Analysis of molecular 
docking-based interaction profiles of the selected 
compounds including Dexamethasone and Hydrocortisone 
revealed that they have formed hydrogen bond (H-bond) 
interactions with several amino acid residues of (1M2Z) , 
particularly residues Asn-564, Arg-611, Gln-642 and Gln-
570. 
Three-dimensional docking model of Dexamethasone, 
Hydrocortisone, compound (4) and compound (11) with the 
target protein (PDB ID: 1M2Z) are portrayed in Fig 3.  This 
figure showed that all compounds have common amino 
acids. We also notice that Dexamethasone and 
Hydrocortisone created two hydrogen bonds with Asn-564.
 
Table 5:  Docking results of 20 novel ligands and standard ligands with the target protein       (PDB ID: 1M2Z) 
Ligand name 
Docking 
Score 
Glide 
energy 
Glide ligand 
efficiency 
N° of H bonds Amino acids 
1 -10.715 -24.666 -0.315 2 Asn564, Arg611 
2 -12.157 -62.966 -0.433 2 Gln570, Asn564 
3 -11.914 -31.967 -0.350 1 Asn564 
4 -13.391 -52.892 -0.462 3  Asn564, Arg611, Gln642 
5 -12.223 -21.673 -0.360 3 Asn564*, Arg611 
6 -12.612 -59.571 -0.467 2  Asn564, Arg611 
7 -11.171 -54.315 -0.385 2 Gln570, Arg611 
8 -11.088 -37.664 -0.358 3 Gln570, Asn564, Gln642 
9 -11.707 -26.112 -0.334 2 Asn564, Leu732 
10 -12.407 -61.132 -0.400 1 Asn564 
11 -14.654 -70.767 -0.532 5 Gln570, Asn564, Thr739, Gln642* 
12 -13.119 -61.249 -0.452 3 Gln570, Asn564, Gln642 
13 -10.371 -20.076 -0.296 3 Gln570, Asn564, Arg611 
14 -13.188 -57.461 -0.440 4 Gln570, Asn564, Gln642* 
15 -11.050 -19.098 -0.335 4  Asn564*, Arg611, Met560 
16 -11.620 -36.280 -0.363 3 Gln570, Asn564, Leu732 
17 -13.060 -54.344 -0.435 4  Asn564*, Arg611, Gln642 
18 -12.676 -48.375 -0.362 4 Met560, Asn564*, Arg611 
19 -10.403 -24.029 -0.306 2 Asn564* 
20 -12.195 -47.126 -0.407 2 Asn564, Gln642 
Dexamethasone -14.209 -56.936 -0.507 5 Gln570, Asn564*, Arg611, Gln642 
Hydrocortisone -13.668 -60.356 -0.526 4 Asn564*, Arg611, Gln642 
*(Two hydrogen bonding interactions with the same amino acid) 
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Figure 2: Three-dimensional docking model of a) Dexamethasone, b) Hydrocortisone, c) compound (4) and d) compound (11) 
with the target protein (PDB ID: 1M2Z) 
 
CONCLUSION 
In this study, Molinspirtion and Osiris guided better 
understanding of the relationship between the 
physicochemical properties and biological activity observed 
for the 20 chosen compounds. Oral bioavailability, molecular 
descriptors, drug likeness properties and bioactivity were 
estimated as per the Lipinski rules of five and results 
outcomes of all compound showed good oral bioavailability. 
Drug relevant properties were predicted, and results 
indicates that all compounds get good drug score. All the 
synthetic compounds were found to have a high degree of 
lipophilicity, which designates a good lipid solubility that 
will help drug to interact with the membranes. Compound 
11 exhibited higher drug score, bioactivity score and 
revealed good drug relevant properties. Furthermore, drug 
likeness analysis suggests that the designed drug derivatives 
require serious transformation in order to obtain 
appropriate oral absorption and brain penetration for 
potential therapeutic applications. 
Comparing the docking values, drug-likeliness, ADME profile 
and toxicity analysis of the derivatives to the parent 
compound Hydrocortisone, the derivatives are found to have 
favorable scores thus suggesting that the problem of poor 
bioavailability, pharmacokinetics and solubility can be 
overcome by structural changes, and serve as promising lead 
candidates for alternative anti-asthma therapy. We should 
mention that Bioinformatics analyses and molecular docking 
gives only suggestion or prediction, these data may do not 
reflect real biological properties. So, bioavailability, 
pharmacokinetic or toxicity should be verified on animals 
with special authorization.  
This article is distributed under the terms of the Creative Commons 
Attribution- NonCommercial 4.0 International License 
(http://creativecommons.org/licenses/by-nc/4.0/), which permits 
any noncommercial use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original 
author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made 
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